BR9612126A - Derivados de benzazepina - Google Patents

Derivados de benzazepina

Info

Publication number
BR9612126A
BR9612126A BR9612126A BR9612126A BR9612126A BR 9612126 A BR9612126 A BR 9612126A BR 9612126 A BR9612126 A BR 9612126A BR 9612126 A BR9612126 A BR 9612126A BR 9612126 A BR9612126 A BR 9612126A
Authority
BR
Brazil
Prior art keywords
benzazepine derivatives
benzazepine
derivatives
Prior art date
Application number
BR9612126A
Other languages
English (en)
Inventor
Kazumi Kondo
Yoshihisa Tanada
Muneaki Kurimura
Seiji Morita
Toyoki Mori
Yoichi Yabuuchi
Minoru Uchida
Tomoichi Shinohara
Hidenori Ogawa
Keizo Kan
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26505504&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9612126(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR9612126A publication Critical patent/BR9612126A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9612126A 1995-12-15 1996-12-13 Derivados de benzazepina BR9612126A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP32613695 1995-12-15
JP18950096 1996-07-18
PCT/JP1996/003652 WO1997022591A1 (en) 1995-12-15 1996-12-13 Benzazepine derivatives with vasopressin agonistic activity

Publications (1)

Publication Number Publication Date
BR9612126A true BR9612126A (pt) 1999-02-17

Family

ID=26505504

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9612126A BR9612126A (pt) 1995-12-15 1996-12-13 Derivados de benzazepina

Country Status (15)

Country Link
US (1) US6096736A (pt)
EP (1) EP0877736B1 (pt)
KR (1) KR100493503B1 (pt)
CN (1) CN1104419C (pt)
AR (1) AR005044A1 (pt)
AT (1) ATE264845T1 (pt)
BR (1) BR9612126A (pt)
DE (1) DE69632268T2 (pt)
DK (1) DK0877736T3 (pt)
ES (1) ES2219703T3 (pt)
HK (1) HK1016973A1 (pt)
MX (1) MX9804849A (pt)
PT (1) PT877736E (pt)
TW (1) TW359669B (pt)
WO (1) WO1997022591A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1162429C (zh) * 1997-07-30 2004-08-18 惠氏公司 三环后叶加压素激动剂
US6194407B1 (en) 1997-07-30 2001-02-27 American Home Products Corporation Tricyclic pyrido vasopressin agonists
US6511974B1 (en) 1997-07-30 2003-01-28 Wyeth Tricyclic vasopressin agonists
ATE277050T1 (de) * 1997-07-30 2004-10-15 Wyeth Corp Trizyclische vasopressin agoniste
US7138393B2 (en) 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
US6090803A (en) * 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
US7053083B2 (en) 2001-04-12 2006-05-30 Wyeth Cyclohexylphenyl vasopressin agonists
BR0208823A (pt) 2001-04-12 2004-03-09 Wyeth Corp Composto, método de tratamento de distúrbios que são remediados ou aliviados pela atividade de agonista de vasopressina em um mamìfero necessitando do mesmo, e, composição farmacêutica
BR0214224A (pt) 2001-11-16 2004-09-21 Yamanouchi Pharma Co Ltd Derivado de 4,4-diflúor-1,2,3,4-tetrahidro-5h-1-benzazepina ou sal do mesmo
KR100882154B1 (ko) 2003-04-28 2009-02-06 아스텔라스세이야쿠 가부시키가이샤 4,4-디플루오로-1,2,3,4-테트라하이드로-5h-1-벤즈아제핀 유도체 또는 이의 염 및 이를 포함하는 의약 조성물
JP2008515956A (ja) * 2004-10-12 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 11β−ヒドロキシステロイドデヒドロゲナーゼ1型活性スピロ化合物
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
CN101203218A (zh) * 2005-04-22 2008-06-18 惠氏公司 苯并呋喃基链烷胺衍生物和其作为5-ht2c激动剂的用途
JP2008538581A (ja) * 2005-04-22 2008-10-30 ワイス {[(2r)−7−(2,6−ジクロロフェニル)−5−フルオロ−2,3−ジヒドロ−1−ベンゾフラン−2−イル]メチル}アミン塩酸塩の結晶形態
CN101175740A (zh) * 2005-04-22 2008-05-07 惠氏公司 二氢苯并呋喃衍生物和其用途
JP2008538577A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
CA2606064A1 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
WO2007051811A2 (en) * 2005-11-01 2007-05-10 Transtech Pharma Pharmaceutical use of substituted amides
EP1948190A2 (en) * 2005-11-01 2008-07-30 Transtech Pharma Pharmaceutical use of substituted amides
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
JP2009530346A (ja) * 2006-03-21 2009-08-27 ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー メタボリックシンドロームの治療用のアダマンタン誘導体
BRPI0709163A2 (pt) * 2006-03-24 2011-06-28 Wyeth Corp tratamento da dor
RU2008135326A (ru) * 2006-03-24 2010-04-27 Вайет (Us) Терапевтические композиции для лечения депрессии
WO2007115935A1 (en) 2006-04-07 2007-10-18 High Point Pharmaceuticals, Llc 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
JP2009539937A (ja) * 2006-06-16 2009-11-19 ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー 置換型ピペリジンカルボキサミドの医薬的使用
US8048908B2 (en) * 2006-07-13 2011-11-01 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
EP1878721A1 (en) * 2006-07-13 2008-01-16 Novo Nordisk A/S 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2008101907A2 (en) * 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
JP2010519240A (ja) * 2007-02-23 2010-06-03 ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての、n−アダマンチルベンズアミド
WO2008101914A2 (en) 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
JP2010519239A (ja) * 2007-02-23 2010-06-03 ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害因子としてのn−アドマンチルベンザミド
AU2007349112A1 (en) * 2007-03-09 2008-09-18 High Point Pharmaceuticals, Llc Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors
JP2010522766A (ja) * 2007-03-28 2010-07-08 ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー 11ベータ−hsd1活性化合物
EP2152081B1 (en) * 2007-04-11 2012-10-24 High Point Pharmaceuticals, LLC Novel compounds
EP2150109B1 (en) * 2007-04-24 2012-09-19 High Point Pharmaceuticals, LLC Pharmaceutical use of substituted amides
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
GB201005623D0 (en) 2010-04-01 2010-05-19 Vantia Ltd New polymorph
RU2642783C2 (ru) * 2012-12-26 2018-01-26 Санва Кагаку Кенкюсо Ко., Лтд. Новое производное бензоазепина и его медицинское применение
TWI643847B (zh) * 2014-06-11 2018-12-11 日商三和化學研究所股份有限公司 Novel benzoazepine derivatives and their medical uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
KR0167349B1 (ko) * 1989-10-20 1999-02-18 오스카 아끼히꼬 벤조헤테로 고리 화합물
TW198715B (pt) * 1991-04-19 1993-01-21 Dtsuka Seiyaku Kk
JPH05320135A (ja) * 1992-05-19 1993-12-03 Yamanouchi Pharmaceut Co Ltd テトラヒドロベンズアゼピン誘導体
WO1994001113A1 (en) * 1992-07-02 1994-01-20 Otsuka Pharmaceutical Company, Limited Oxytocin antagonist
TW270927B (pt) * 1992-10-16 1996-02-21 Otsuka Pharma Co Ltd
WO1994020473A1 (en) * 1993-03-11 1994-09-15 Yamanouchi Pharmaceutical Co., Ltd. Compound with vasopressin antagonism
GB9307527D0 (en) * 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
DE69535486T2 (de) * 1994-06-15 2008-04-10 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclische Verbindungen verwendbar als Vasopressin- oder Oxytocin-Modulatoren

Also Published As

Publication number Publication date
PT877736E (pt) 2004-09-30
CN1209121A (zh) 1999-02-24
DK0877736T3 (da) 2004-08-16
ATE264845T1 (de) 2004-05-15
WO1997022591A1 (en) 1997-06-26
TW359669B (en) 1999-06-01
AR005044A1 (es) 1999-04-07
US6096736A (en) 2000-08-01
EP0877736A1 (en) 1998-11-18
ES2219703T3 (es) 2004-12-01
EP0877736B1 (en) 2004-04-21
MX9804849A (es) 1998-09-30
KR100493503B1 (ko) 2005-09-30
DE69632268T2 (de) 2005-04-21
CN1104419C (zh) 2003-04-02
DE69632268D1 (de) 2004-05-27
KR20000064406A (ko) 2000-11-06
HK1016973A1 (en) 1999-11-12

Similar Documents

Publication Publication Date Title
BR9612126A (pt) Derivados de benzazepina
PT833828E (pt) Derivados de rapamicina
DE69522717D1 (de) Chinazolinderivate
DE69611361D1 (de) Chinazolin-derivate
NO974103L (no) Arylsulfonylaminohydroksamsyre-derivater
DE69610698D1 (de) Chinazolin-derivate
BR9609682A (pt) Foto-desinfetantes de baixa nuança
BR9611834A (pt) Derivados de oximetóxi-3-aril-pirona
BR9605434A (pt) Derivados de purin-6-ona
ATE199150T1 (de) Diphenylmethylenpiperidin-derivate
DE69601527D1 (de) Pyrrolylbenzimidazol-Derivate
ATA100695A (de) Prothrombin-derivate
PT856007E (pt) Derivados de ciclopeptidos
BR9610597A (pt) Derivados de diarilalcenilamina
DE69627830D1 (de) Pyrazol-derivate
ATE202093T1 (de) 4-amino-benzoylguanidin-derivate
ATE177102T1 (de) Chromanderivate
DE59610106D1 (de) Fluorbenzylether-Derivate
PT843675E (pt) Derivados de aza-antraciclinona
BR9603508A (pt) Derivados de alquenil-benzoilguanidina
BR9609813A (pt) Derivados de hidrazina
PT839024E (pt) Formulacoes de monensina
DE59607055D1 (de) 4-Mercapto-benzoylguanidin-Derivate
DE69620514T2 (de) 5-aminoflavon-derivate
ATA45796A (de) Lysin-prolin-derivate

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/05/2008, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061558/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO0132272-32.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: NYCOMED GMBH, OKLAHOMA STATE UNIVERSITY, REGESTS OF THE UNIVERSITY OF MINNESOTA, OTSUKA PHARMACEUTICAL CO LTD, PLASMASEAL CORPORATION

B21B Extinction acc. art. 78, item ii - on waiver by the patentee, without prejudice to the rights of third parties

Free format text: SOLICITADA ATRAVES DA PETICAO 860130003851, DE 04/10/2013

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.061558/2013-85 13A VARA FEDERAL DO RIO DE JANEIRO ORDINARIA / PROPRIEDADE INDUSTRIAL PROCESSO : 0132272-32.2013.4.02.5101 (2013.51.01.132272-3) AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL INPI REU: REGENTS OF THE UNIVERSITY OF MINNESOTA, OKLAHOMA STATE UNIVERSITY, OTSUKA PHARMACEUTICAL CO. LTD., PLASMASEAL CORPORATION E NYCOMED GMBH. DECISAO: HOMOLOGO, POR SENTENCA, PARA QUE SE PRODUZA OS SEUS JURIDICOS E LEGAIS EFEITOS, OS ACORDOS FIRMADOS ENTRE O INPI E AS RES, CONFORME FLS. 87/89, 93/96, 138/139, 192/193 E 245, JULGANDO EXTINTO O PROCESSO, COM RESOLUCAO DO MERITO, NOS MOLDES DO ARTIGO 269, III DO CODIGO DO PROCESSO CIVIL, EM RELACAO AS ALUDIDAS EMPRESAS RES E AO